Annual FCF
-$2.47 M
+$23.16 M+90.37%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual free cash flow is -$2.47 million, with the most recent change of +$23.16 million (+90.37%) on December 31, 2023.
- During the last 3 years, PLX annual FCF has risen by +$24.29 million (+90.78%).
- PLX annual FCF is now -106.45% below its all-time high of $38.26 million, reached on December 31, 2009.
Performance
PLX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$4.02 M
+$7.80 M+206.24%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly free cash flow is $4.02 million, with the most recent change of +$7.80 million (+206.24%) on September 30, 2024.
- Over the past year, PLX quarterly FCF has increased by +$11.35 million (+154.78%).
- PLX quarterly FCF is now -93.14% below its all-time high of $58.57 million, reached on December 31, 2009.
Performance
PLX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
$7.17 M
+$11.35 M+271.47%
September 30, 2024
Summary
- As of February 8, 2025, PLX TTM free cash flow is $7.17 million, with the most recent change of +$11.35 million (+271.47%) on September 30, 2024.
- Over the past year, PLX TTM FCF has increased by +$15.81 million (+183.04%).
- PLX TTM FCF is now -81.26% below its all-time high of $38.26 million, reached on December 31, 2009.
Performance
PLX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
PLX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +90.4% | +154.8% | +183.0% |
| 3 y3 years | +90.8% | +154.8% | +183.0% |
| 5 y5 years | +70.7% | +154.8% | +183.0% |
PLX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +90.4% | -15.8% | +143.4% | at high | +125.3% |
| 5 y | 5-year | at high | +90.8% | -35.6% | +139.3% | at high | +124.1% |
| alltime | all time | -106.5% | +94.7% | -93.1% | +128.1% | -81.3% | +115.5% |
Protalix BioTherapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.02 M(-206.2%) | $7.17 M(-271.5%) |
| Jun 2024 | - | -$3.78 M(-205.3%) | -$4.18 M(-195.7%) |
| Mar 2024 | - | $3.59 M(+7.3%) | $4.37 M(-277.1%) |
| Dec 2023 | -$2.47 M(-90.4%) | $3.35 M(-145.6%) | -$2.47 M(-71.4%) |
| Sep 2023 | - | -$7.33 M(-253.8%) | -$8.64 M(-18.2%) |
| Jun 2023 | - | $4.77 M(-246.9%) | -$10.56 M(-53.7%) |
| Mar 2023 | - | -$3.25 M(+14.9%) | -$22.82 M(-11.0%) |
| Dec 2022 | -$25.63 M(+118.2%) | -$2.82 M(-69.5%) | -$25.63 M(-9.6%) |
| Sep 2022 | - | -$9.26 M(+23.8%) | -$28.34 M(+33.0%) |
| Jun 2022 | - | -$7.48 M(+23.5%) | -$21.30 M(+180.9%) |
| Mar 2022 | - | -$6.06 M(+9.4%) | -$7.58 M(-35.4%) |
| Dec 2021 | -$11.74 M(-56.1%) | -$5.54 M(+148.9%) | -$11.74 M(-16.3%) |
| Sep 2021 | - | -$2.22 M(-135.7%) | -$14.03 M(-9.6%) |
| Jun 2021 | - | $6.24 M(-161.0%) | -$15.52 M(-47.9%) |
| Mar 2021 | - | -$10.22 M(+30.6%) | -$29.80 M(+11.3%) |
| Dec 2020 | -$26.76 M(+33.9%) | -$7.83 M(+111.1%) | -$26.76 M(+18.1%) |
| Sep 2020 | - | -$3.71 M(-53.9%) | -$22.65 M(+0.4%) |
| Jun 2020 | - | -$8.05 M(+12.0%) | -$22.56 M(+14.4%) |
| Mar 2020 | - | -$7.18 M(+93.4%) | -$19.72 M(-1.3%) |
| Dec 2019 | -$19.98 M(+137.1%) | -$3.71 M(+2.7%) | -$19.98 M(-2.3%) |
| Sep 2019 | - | -$3.62 M(-30.5%) | -$20.46 M(+518.2%) |
| Jun 2019 | - | -$5.21 M(-30.1%) | -$3.31 M(-46.7%) |
| Mar 2019 | - | -$7.45 M(+77.6%) | -$6.21 M(-26.3%) |
| Dec 2018 | -$8.43 M(-23.1%) | -$4.19 M(-131.0%) | -$8.43 M(-164.5%) |
| Sep 2018 | - | $13.54 M(-266.9%) | $13.06 M(-217.2%) |
| Jun 2018 | - | -$8.11 M(-16.1%) | -$11.15 M(-7.0%) |
| Mar 2018 | - | -$9.66 M(-155.8%) | -$11.98 M(+9.3%) |
| Dec 2017 | -$10.96 M(-66.7%) | $17.30 M(-262.0%) | -$10.96 M(-69.3%) |
| Sep 2017 | - | -$10.68 M(+19.4%) | -$35.72 M(+24.7%) |
| Jun 2017 | - | -$8.94 M(+3.4%) | -$28.64 M(-9.7%) |
| Mar 2017 | - | -$8.65 M(+16.0%) | -$31.72 M(-3.7%) |
| Dec 2016 | -$32.95 M(+33.1%) | -$7.46 M(+107.1%) | -$32.95 M(+12.2%) |
| Sep 2016 | - | -$3.60 M(-70.0%) | -$29.35 M(-15.0%) |
| Jun 2016 | - | -$12.02 M(+21.7%) | -$34.54 M(+22.9%) |
| Mar 2016 | - | -$9.88 M(+155.8%) | -$28.10 M(+13.6%) |
| Dec 2015 | -$24.75 M(-17.7%) | -$3.86 M(-56.1%) | -$24.75 M(-4.6%) |
| Sep 2015 | - | -$8.79 M(+57.5%) | -$25.93 M(-3.7%) |
| Jun 2015 | - | -$5.58 M(-14.4%) | -$26.93 M(-3.7%) |
| Mar 2015 | - | -$6.52 M(+29.3%) | -$27.98 M(-6.9%) |
| Dec 2014 | -$30.07 M(-7.6%) | -$5.04 M(-48.5%) | -$30.07 M(+0.3%) |
| Sep 2014 | - | -$9.79 M(+47.8%) | -$29.99 M(+4.4%) |
| Jun 2014 | - | -$6.63 M(-23.0%) | -$28.74 M(-7.1%) |
| Mar 2014 | - | -$8.60 M(+73.3%) | -$30.92 M(-5.0%) |
| Dec 2013 | -$32.54 M(+2171.0%) | -$4.96 M(-41.9%) | -$32.54 M(+25.1%) |
| Sep 2013 | - | -$8.54 M(-3.0%) | -$26.01 M(-1.0%) |
| Jun 2013 | - | -$8.81 M(-13.9%) | -$26.27 M(+474.7%) |
| Mar 2013 | - | -$10.23 M(-751.5%) | -$4.57 M(+218.9%) |
| Dec 2012 | -$1.43 M(-95.1%) | $1.57 M(-117.8%) | -$1.43 M(-86.1%) |
| Sep 2012 | - | -$8.80 M(-168.3%) | -$10.32 M(-3.1%) |
| Jun 2012 | - | $12.89 M(-281.7%) | -$10.65 M(-64.2%) |
| Mar 2012 | - | -$7.09 M(-3.1%) | -$29.77 M(+1.7%) |
| Dec 2011 | -$29.27 M | -$7.32 M(-19.9%) | -$29.27 M(-5.7%) |
| Sep 2011 | - | -$9.13 M(+46.5%) | -$31.03 M(-5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2011 | - | -$6.24 M(-5.4%) | -$32.92 M(-19.7%) |
| Mar 2011 | - | -$6.59 M(-27.3%) | -$41.01 M(-11.5%) |
| Dec 2010 | -$46.32 M(-221.1%) | -$9.07 M(-17.7%) | -$46.32 M(-317.2%) |
| Sep 2010 | - | -$11.02 M(-23.0%) | $21.32 M(-16.4%) |
| Jun 2010 | - | -$14.32 M(+20.3%) | $25.51 M(-24.2%) |
| Mar 2010 | - | -$11.91 M(-120.3%) | $33.64 M(-12.1%) |
| Dec 2009 | $38.26 M(-297.3%) | $58.57 M(-957.2%) | $38.26 M(-264.3%) |
| Sep 2009 | - | -$6.83 M(+10.3%) | -$23.28 M(-1.0%) |
| Jun 2009 | - | -$6.19 M(-15.0%) | -$23.52 M(+6.7%) |
| Mar 2009 | - | -$7.29 M(+145.6%) | -$22.05 M(+13.7%) |
| Dec 2008 | -$19.39 M(+51.6%) | -$2.97 M(-58.0%) | -$19.39 M(-10.0%) |
| Sep 2008 | - | -$7.07 M(+49.5%) | -$21.54 M(+31.1%) |
| Jun 2008 | - | -$4.73 M(+2.2%) | -$16.44 M(+17.1%) |
| Mar 2008 | - | -$4.62 M(-9.7%) | -$14.04 M(+9.8%) |
| Dec 2007 | -$12.78 M(+115.5%) | -$5.12 M(+161.0%) | -$12.78 M(+32.4%) |
| Sep 2007 | - | -$1.96 M(-15.6%) | -$9.65 M(+8.2%) |
| Jun 2007 | - | -$2.33 M(-31.0%) | -$8.92 M(+11.7%) |
| Mar 2007 | - | -$3.37 M(+69.3%) | -$7.99 M(+34.6%) |
| Dec 2006 | -$5.93 M(+46.5%) | -$1.99 M(+62.2%) | -$5.93 M(-16.2%) |
| Sep 2006 | - | -$1.23 M(-11.8%) | -$7.08 M(+20.6%) |
| Jun 2006 | - | -$1.39 M(+5.5%) | -$5.87 M(+30.6%) |
| Mar 2006 | - | -$1.32 M(-57.9%) | -$4.50 M(+40.2%) |
| Dec 2005 | -$4.05 M(+33.2%) | -$3.14 M(>+9900.0%) | -$3.21 M(+92.4%) |
| Sep 2005 | - | -$21.40 K(+18.9%) | -$1.67 M(-1.3%) |
| Jun 2005 | - | -$18.00 K(-41.0%) | -$1.69 M(-1.5%) |
| Mar 2005 | - | -$30.50 K(-98.1%) | -$1.71 M(-2.0%) |
| Dec 2004 | -$3.04 M(+2123.8%) | -$1.60 M(+3603.5%) | -$1.75 M(+888.1%) |
| Sep 2004 | - | -$43.10 K(-0.9%) | -$177.00 K(+14.6%) |
| Jun 2004 | - | -$43.50 K(-34.3%) | -$154.40 K(+0.5%) |
| Mar 2004 | - | -$66.20 K(+173.6%) | -$153.70 K(+12.4%) |
| Dec 2003 | -$136.70 K(-6.8%) | -$24.20 K(+18.0%) | -$136.70 K(-1.5%) |
| Sep 2003 | - | -$20.50 K(-52.1%) | -$138.80 K(-1.6%) |
| Jun 2003 | - | -$42.80 K(-13.0%) | -$141.00 K(+5.6%) |
| Mar 2003 | - | -$49.20 K(+87.1%) | -$133.50 K(-8.9%) |
| Dec 2002 | -$146.60 K(-81.4%) | -$26.30 K(+15.9%) | -$146.60 K(-89.3%) |
| Sep 2002 | - | -$22.70 K(-35.7%) | -$1.37 M(-0.8%) |
| Jun 2002 | - | -$35.30 K(-43.3%) | -$1.38 M(+79.9%) |
| Mar 2002 | - | -$62.30 K(-95.0%) | -$766.00 K(-3.0%) |
| Dec 2001 | -$789.40 K(+1386.6%) | -$1.25 M(+3609.8%) | -$789.40 K(-233.2%) |
| Sep 2001 | - | -$33.60 K(-105.8%) | $592.70 K(+2.4%) |
| Jun 2001 | - | $576.40 K(-772.6%) | $578.70 K(-1140.8%) |
| Mar 2001 | - | -$85.70 K(-163.2%) | -$55.60 K(+4.7%) |
| Dec 2000 | -$53.10 K(-96.3%) | $135.60 K(-384.9%) | -$53.10 K(-80.8%) |
| Sep 2000 | - | -$47.60 K(-17.8%) | -$276.50 K(-55.6%) |
| Jun 2000 | - | -$57.90 K(-30.4%) | -$623.20 K(-36.1%) |
| Mar 2000 | - | -$83.20 K(-5.2%) | -$975.00 K(-32.2%) |
| Dec 1999 | -$1.44 M(+37.0%) | -$87.80 K(-77.7%) | -$1.44 M(+6.5%) |
| Sep 1999 | - | -$394.30 K(-3.8%) | -$1.35 M(+41.3%) |
| Jun 1999 | - | -$409.70 K(-24.9%) | -$955.20 K(+75.1%) |
| Mar 1999 | - | -$545.50 K | -$545.50 K |
| Dec 1998 | -$1.05 M(+323.4%) | - | - |
| Dec 1997 | -$247.90 K(+510.6%) | - | - |
| Dec 1996 | -$40.60 K | - | - |
FAQ
- What is Protalix BioTherapeutics annual free cash flow?
- What is the all time high annual FCF for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual FCF year-on-year change?
- What is Protalix BioTherapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly FCF year-on-year change?
- What is Protalix BioTherapeutics TTM free cash flow?
- What is the all time high TTM FCF for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics TTM FCF year-on-year change?
What is Protalix BioTherapeutics annual free cash flow?
The current annual FCF of PLX is -$2.47 M
What is the all time high annual FCF for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual free cash flow is $38.26 M
What is Protalix BioTherapeutics annual FCF year-on-year change?
Over the past year, PLX annual free cash flow has changed by +$23.16 M (+90.37%)
What is Protalix BioTherapeutics quarterly free cash flow?
The current quarterly FCF of PLX is $4.02 M
What is the all time high quarterly FCF for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly free cash flow is $58.57 M
What is Protalix BioTherapeutics quarterly FCF year-on-year change?
Over the past year, PLX quarterly free cash flow has changed by +$11.35 M (+154.78%)
What is Protalix BioTherapeutics TTM free cash flow?
The current TTM FCF of PLX is $7.17 M
What is the all time high TTM FCF for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high TTM free cash flow is $38.26 M
What is Protalix BioTherapeutics TTM FCF year-on-year change?
Over the past year, PLX TTM free cash flow has changed by +$15.81 M (+183.04%)